Last deal

$120M

Amount

Post-IPO Equity

Stage

10.05.2024

Date

3

all rounds

$369.74M

Total amount

date founded

Financing round

General

About Company
ITeos Therapeutics is a biotechnology company specializing in tumor immunology and cancer immunotherapy.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2011

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Leveraging the expertise of the Ludwig Cancer Research Institute, ITeos Therapeutics is developing small molecule immunomodulators to target the tumor microenvironment and inhibit cancer-induced immune suppression. By enhancing the clinical efficacy of standard cancer treatments and newer immunomodulatory therapies, such as immune checkpoint blockade, their product candidates, including EOS-850 and EOS-448, aim to restore the immune response against cancer. With a focus on highly differentiated immuno-oncology therapeutics, ITeos Therapeutics is advancing its pipeline of novel product candidates, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant. Headquartered in Cambridge, MA, with a research center in Gosselies, Belgium, the company is committed to developing innovative solutions for cancer patients.
Contacts

Phone number

Social url

Similar Companies
1000
IOmx Therapeutics

IOmx Therapeutics

iOmx Therapeutics is a company that develops cancer therapeutics targeting immune checkpoint modulators on tumor cells.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Munich, Germany

total rounds

2

total raised

$103.24M
Evoq Therapeutics

Evoq Therapeutics

Evoq Therapeutics is a cancer immunotherapy company that aims to unleash the full potential of cancer vaccines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

total rounds

1

total raised

$2M
ImmunOs Therapeutics

ImmunOs Therapeutics

ImmunOs Therapeutics is a clinical-stage biotech developing novel human immunomodulatory proteins for cancer and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

8952 Schlieren, Switzerland

total rounds

6

total raised

$75.04M
Neon Therapeutics

Neon Therapeutics

Neon Therapeutics develops personalized vaccines and autologous T-cell therapies for cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

3

total raised

$161M

Financials

Funding Rounds
9
3

Number of Funding Rounds

$369.74M

Money Raised

Their latest funding was raised on 10.05.2024. Their latest investor RA Capital Management. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
30.01.2020
$16.54M
Local Amount - EUR 15M
RA Capital Management

RA Capital Management

RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Health Care, Financial Services

Location

Boston, MA, USA

count Of Investments

381

count Of Exists

33
Boxer Capital

Boxer Capital

Boxer Capital supports biotech public companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology

Location

Windermere, FL 34786, USA

count Of Investments

91

count Of Exists

7
RA Capital Management

RA Capital Management

RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Health Care, Financial Services

Location

Boston, MA, USA

count Of Investments

381

count Of Exists

33
Boxer Capital

Boxer Capital

Boxer Capital supports biotech public companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology

Location

Windermere, FL 34786, USA

count Of Investments

91

count Of Exists

7
Co-Investors
Investors
17
3

Number of lead investors

17

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Equity
Yes
Post-IPO Equity
No
Series B
RA Capital Management

RA Capital Management

RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Health Care, Financial Services

Location

Boston, MA, USA

count Of Investments

381

count Of Exists

33
Boxer Capital

Boxer Capital

Boxer Capital supports biotech public companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology

Location

Windermere, FL 34786, USA

count Of Investments

91

count Of Exists

7
curative ventures

curative ventures

Curative Ventures is a venture capital firm that partners with biotech companies to develop innovative therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Dallas, TX, USA

count Of Investments

4

count Of Exists

1

People

Founders
2

Benoît Van den Eynde

Benoît Van den Eynde is the Co-Founder of ITeos Therapeutics.

current job

ITeos Therapeutics
ITeos Therapeutics

organization founded

1

Benoît Van den Eynde

Michel Detheux
Michel Detheux

Michel Detheux

Dr. Michel Detheux is the co-founder, President, and Chief Executive Officer of iTeos Therapeutics. He has held the role of Chief Executive Officer since the company’s inception in 2012. During his tenure, Michel has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, he spearheaded the strategic collaboration with GlaxoSmithKline in 2021 to co-develop and co-commercialize iTeos’ differentiated anti-TIGIT antibody for a total value of $2B. He previously served as a director at Ludwig Cancer Research and worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen). Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in Biochemistry from Université Catholique de Louvain, and a business certificate from Solvay Business School.

current job

ITeos Therapeutics
ITeos Therapeutics

organization founded

1

Michel Detheux

Employee Profiles
13
Yvonne McGrath

Yvonne McGrath

Chief Scientific Officer

Cédric Iteos

Senior human resources consultant

Matthew Gall

Matthew Gall

Chief Financial Officer

Catherine Hoofd

Senior scientist

Julia Cuende

Research scientist

Michel Detheux

Michel Detheux

Co-Founder, President & CEO

Alfred Gray

Director business development

Yves Mertens

Yves Mertens

CFO

Activity

Recent News
8
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week